Khan Aujala Irfan, Mashat Ghadi D, Hazique Mohammad, Khan Kokab Irfan, Ramesh Prasana, Kanagalingam Suthasenthuran, Zargham Ul Haq Fnu, Victory Srinivasan Nishok, Khan Safeera
Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Pediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2022 Oct 4;14(10):e29920. doi: 10.7759/cureus.29920. eCollection 2022 Oct.
The purpose of this study was to systematically review the current evidence on apatinib and offer a better understanding of its safety and efficacy in metastatic colorectal cancer (mCRC) patients who have not responded to standard chemotherapies. This systematic review was conducted using research from the last 10 years (May 30, 2012, to May 30, 2022) and was obtained from the following databases: PubMed, PubMed Central (PMC), ScienceDirect, and Google Scholar. After removing duplicates, screening titles and abstracts, and applying eligibility criteria and quality appraisal, 11 articles were left for this systematic review (one meta-analysis, eight non-randomized studies, and two traditional reviews). Out of the 11 studies, six were on apatinib monotherapy, while three were on apatinib combination therapy. Apatinib has demonstrated efficacy in the monotherapy and combination therapy trials and has exhibited an acceptable safety profile as the adverse events were predominantly graded 1-2 and could be easily managed. Therefore, apatinib is an encouraging candidate for third-line therapy in chemotherapy-refractory mCRC patients. This conclusion should be confirmed and validated by studies with larger, randomized clinical trials to gain better insight and to directly compare the efficacy and safety of apatinib with all current third-line therapies together so that clinicians can easily assess which treatment modality is superior for chemotherapy-refractory mCRC patients.
本研究的目的是系统回顾关于阿帕替尼的现有证据，并更好地了解其在对标准化疗无反应的转移性结直肠癌（mCRC）患者中的安全性和疗效。本系统评价采用了过去10年（2012年5月30日至2022年5月30日）的研究，数据来源于以下数据库：PubMed、PubMed Central（PMC）、ScienceDirect和谷歌学术。在去除重复项、筛选标题和摘要，并应用纳入标准和质量评估后，本系统评价最终纳入11篇文章（1篇荟萃分析、8篇非随机研究和2篇传统综述）。在这11项研究中，6项是关于阿帕替尼单药治疗，3项是关于阿帕替尼联合治疗。阿帕替尼在单药治疗和联合治疗试验中均显示出疗效，并且安全性良好，因为不良事件主要为1-2级，易于处理。因此，阿帕替尼是化疗难治性mCRC患者三线治疗的一个有前景的选择。这一结论应通过更大规模的随机临床试验进行证实和验证，以便更好地了解并直接比较阿帕替尼与所有现有三线治疗的疗效和安全性，从而使临床医生能够轻松评估哪种治疗方式对化疗难治性mCRC患者更具优势。
